Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Fate Therapeutics (FATE) has a market cap of $0.15 billion USD. According to our data, Fate Therapeutics is ranked No.7363 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $0.15 B |
-19.09%
|
| Dec 31, 2024 | $0.19 B |
-55.88%
|
| Dec 29, 2023 | $0.43 B |
-62.93%
|
| Dec 30, 2022 | $1.15 B |
-82.76%
|
| Dec 31, 2021 | $6.66 B |
-35.65%
|
| Dec 31, 2020 | $10.36 B |
364.64%
|
| Dec 31, 2019 | $2.23 B |
52.53%
|
| Dec 31, 2018 | $1.46 B |
109.98%
|
| Dec 29, 2017 | $0.70 B |
143.43%
|
| Dec 30, 2016 | $0.29 B |
-25.52%
|
| Dec 31, 2015 | $0.38 B |
-33.00%
|
| Dec 31, 2014 | $0.57 B |
-19.90%
|
| Dec 31, 2013 | $0.72 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$1.11 B |
-0.000 M
|
USA
|
 bluebird bio
BLUE
|
$77.49 M |
-0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.24 B |
0.000 M
|
USA
|
 Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
 Precision BioSciences
DTIL
|
$38.43 M |
0.000 M
|
USA
|
 Adaptimmune Therapeutics
ADAP
|
$0.14 B |
0.000 M
|
UK
|
 Atara Biotherapeutics
ATRA
|
$39.63 M |
0.000 M
|
USA
|
 Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
 Novartis
NVS
|
$196.25 B |
0.003 M
|
Switzerland
|
 Bristol-Myers Squibb
BMY
|
$115.77 B |
0.000 M
|
USA
|
| Market Cap | = | FATE Stock Price | * | FATE Shares Outstanding |
| = | $1.34 | * | 0.11 B | |
| = | $0.15 B |